Harmony Gold Mining reports 61% operating profit surge but output decline and copper capex weigh on HMY stock
Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?
Read More 5 minute read Retail Industry News Rashi Peripherals (NSE: RPTECH) EBITDA rises in Q2 FY26 but PAT slips on ESOP cost: What does this mean for the stock’s outlook? Rashi Peripherals Q2 FY26 earnings show 12% revenue growth and 4% EBITDA rise. See how ESOP costs impacted PAT and what’s next for RPTECH. byPallavi MadhirajuNovember 8, 2025